Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas

Publisher： Karger

E-ISSN： 1423-0232|92|3|170-172

ISSN： 0030-2414

Source： Oncology, Vol.92, Iss.3, 2016-11, pp. : 170-172

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 8, 2015-08 ,pp. : 623-627

John Wiley & Sons Inc

Access to resources Recommend Favorite

High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-03 ,pp. : 155-163

Karger

Access to resources Recommend Favorite

Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases

By  

CANCER, Vol. 124, Iss. 4, 2018-02 ,pp. : 807-815

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 32-39

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current Status and Perspectives of Targeted Therapy in Well-Differentiated Neuroendocrine Tumors

By  

Oncology, Vol. 83, Iss. 3, 2012-07 ,pp. : 117-127

Karger

Access to resources Recommend Favorite